Migraines and Medicinal Cannabis: How Clinicians Approach Ongoing Management

For those who live with migraines, the experience is rarely just about a headache. It is often a total-body event, marked by a frustrating unpredictability that can make even simple daily plans feel out of reach. In Aotearoa New Zealand, the medical understanding of this condition is shifting. We no longer see migraines as a subjective symptom to be ignored, but as a complex neurological pathology that requires a steady, guided approach to management.

When standard treatments have been trialled without success, many people find themselves looking for a fresh perspective. Medicinal cannabis is increasingly becoming part of that conversation, not as a quick fix, but as a potential tool within a professional, clinician-led framework designed to help you regain a sense of balance.

More Than Just a Headache

A migraine is fundamentally a condition of the nervous system. To ensure the right support is provided, clinicians start by distinguishing these episodes from other types of pain, such as tension headaches. According to the International Classification of Headache Disorders, a formal diagnosis usually involves a history of recurrent attacks that can last anywhere from 4 to 72 hours.

These attacks often carry specific characteristics, such as a pulsating sensation on one side of the head or pain that becomes worse with routine movement. For many, the physical pain is accompanied by nausea or a heightened sensitivity to light and sound. By understanding these patterns, clinicians can better monitor whether a condition is episodic or if it is beginning to progress into a chronic state, which is defined as experiencing symptoms on 15 or more days per month.

Looking at the Internal Balance

Current research suggests that migraines may be linked to the way our brain signals pain through the trigeminovascular system. There is also significant interest in the role of the endocannabinoid system, or ECS, which acts as a natural regulator within our bodies.

One theory of growing interest is Clinical Endocannabinoid Deficiency. This suggests that some individuals may have a lower “tone” or level of natural cannabinoids, such as anandamide, which helps the body manage pain thresholds. Research has found that people with chronic migraines often have lower levels of these natural compounds in their system. In this context, medicinal cannabis is viewed as a potential way to supplement this deficiency and help stabilise the neurological environment.

The Importance of a Personalised Assessment

In New Zealand, the journey begins with a thorough medical review. Medicinal cannabis is typically considered for those who have found that conventional options, such as triptans or preventative tablets, are either ineffective or difficult to tolerate.

The initial consultation is a time for a calm, detailed discussion about your health history. Clinicians use safety checklists, and screening questions, to ensure there are no “red flags” that might point to other underlying issues. This process is not about jumping to conclusions, but about building a safe, evidence-led foundation for your care.

Two Paths: Steady Support and Responsive Care

Professional migraine management generally follows two distinct but complementary pathways: keeping the frequency of attacks down and managing them when they do happen.

Foundations for Prevention

For those who face frequent attacks, the goal is often to reduce the overall “volume” of the condition. This usually involves a daily routine of CBD-dominant oils. Because CBD is non-intoxicating and has anti-inflammatory properties, it is used to help settle the nervous system over time. This is a gradual process, often taking several weeks of consistent use to see the full effect.

Support at the Onset

When a migraine does occur, the priority is rapid relief to prevent the symptoms from escalating. For this, clinicians may discuss the use of balanced THC and CBD formulations delivered via a vaporiser. A recent clinical trial showed that a flower with a specific 1:2 ratio of THC to CBD was significantly more effective than a placebo at achieving pain freedom within two hours. This method allows the cannabinoids to enter the system quickly, which many find more helpful than waiting for an oil to be digested.

Measuring What Matters to You

Moving away from the trial and error that can be so exhausting, clinicians use validated scales to track how a treatment plan is impacting your life. Rather than just focusing on a pain score, tools like the Migraine Disability Assessment (MIDAS) look at the bigger picture. This scale measures how many days you have missed or been less productive at work, school, or with your family over a three-month period.

By reviewing these scores during follow-up consultations, which usually happen every three months, you and your doctor can see an objective map of your progress. This data helps in making precise adjustments to your dosage or product ratio, ensuring the plan remains sustainable and effective.

Navigating Limits and Safety

While the potential for relief is a source of hope, it is important to be aware of the risks. One common concern is Medication Overuse Headache, which can happen if acute relief options are used too often, potentially making the underlying condition worse. This condition is well demonstrated with conventional treatments,however it is too early to say if this occurs with Cannabinoids as there have not been studies demonstrating this. However, to avoid this, many clinicians recommend limiting acute treatments to fewer than 10 or 15 days per month.

Your clinician will also monitor for any interactions with other medications you may be taking, such as those for blood pressure or depression, to ensure your entire regimen is working in harmony. The focus is always on a steady, long-term improvement in your quality of life rather than a temporary solution.

A Compassionate Path Forward

Living with a long-term condition like migraine can be fatiguing, and the search for the right management often requires patience. The clinical approach to medicinal cannabis in New Zealand is designed to offer a supportive structure, ensuring every step you take is led by both empathy and evidence.

If you feel that a more guided, clinician-led approach to your migraine management could be the right path for you, we invite you to explore your options in a professional and judgment-free space.

References

1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. (2018). Cephalalgia, 38(1), 1–211. https://doi.org/10.1177/0333102417738202
2. An overview of medicinal cannabis for health practitioners – bpacnz. https://bpac.org.nz/2022/medicinal-cannabis.aspx
3. Migraine Diagnosis | Science of Migraine. https://www.scienceofmigraine.com/management/migraine-diagnosis-criteria
4. Russo, E. B. (2016). Clinical endocannabinoid deficiency reconsidered: Current research supports the theory in migraine, fibromyalgia, irritable bowel, and other Treatment-Resistant syndromes. Cannabis and Cannabinoid Research, 1(1), 154–165. https://doi.org/10.1089/can.2016.0009
5. Sarchielli, P., Pini, L. A., Coppola, F., Rossi, C., Baldi, A., Mancini, M. L., & Calabresi, P. (2006). Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology, 32(6), 1384–1390. https://doi.org/10.1038/sj.npp.1301246
6. Migraine Foundation Aotearoa New Zealand. Preventive medications for migraine. Published April 2025. Accessed February 17, 2026. https://migrainefoundation.org.nz/wp-content/uploads/2025/04/Preventive-medications-for-migraine-Updated-April-2025.pdf
7. Cannabis Clinic. (2023, September 7). Medicinal Cannabis & CBD for migraines | Cannabis Clinic NZ. https://cannabisclinic.co.nz/manage-your-migraines-with-cbd-oil/
8. Schuster, N. M., Wallace, M. S., Marcotte, T. D., Buse, D. C., Lee, E., Liu, L., & Sexton, M. (2026). Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial. Headache, 66(2), 365–376. https://doi.org/10.1111/head.70025
9. Stewart, W. F., Lipton, R. B., Dowson, A. J., & Sawyer, J. (2001). Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology, 56(suppl_1), S20-8. https://doi.org/10.1212/wnl.56.suppl_1.s20
10. Kosinski, M., Bayliss, Bjorner, J., Ware, J., Garber, W., Batenhorst, A., Cady, R., Dahlöf, C., Dowson, A., & Tepper, S. (2003). A six-item short-form survey for measuring headache impact: The HIT-6TM. Quality of Life Research, 12(8), 963–974. https://doi.org/10.1023/a:1026119331193
11. Zhang, N., & Woldeamanuel, Y. W. (2021). Medication overuse headache in patients with chronic migraine using cannabis: A case–referent study. Headache the Journal of Head and Face Pain, 61(8), 1234–1244. https://doi.org/10.1111/head.14195